Needham & Company LLC Reaffirms Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. They currently have a $5.00 price objective on the biopharmaceutical company's stock. Needham & Company LLC's price objective would indicate a potential upside of 390.20% from the stock's current price.

Several other equities analysts have also recently issued reports on the company. JMP Securities reiterated a "market outperform" rating and set a $4.00 price target (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. The Goldman Sachs Group began coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, March 20th. Finally, Cantor Fitzgerald initiated coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, Esperion Therapeutics has an average rating of "Hold" and a consensus price target of $6.58.

Remove Ads

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock traded up $0.06 on Tuesday, hitting $1.02. The company had a trading volume of 8,623,619 shares, compared to its average volume of 5,690,821. Esperion Therapeutics has a 52 week low of $0.93 and a 52 week high of $3.94. The company has a market cap of $201.81 million, a PE ratio of -1.59 and a beta of 0.86. The business has a 50-day simple moving average of $1.58 and a 200-day simple moving average of $2.02.

Institutional Trading of Esperion Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Mackenzie Financial Corp raised its position in Esperion Therapeutics by 116.1% during the fourth quarter. Mackenzie Financial Corp now owns 143,252 shares of the biopharmaceutical company's stock valued at $315,000 after buying an additional 76,965 shares during the period. Two Sigma Advisers LP increased its holdings in shares of Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock valued at $7,956,000 after purchasing an additional 16,100 shares during the period. Rafferty Asset Management LLC purchased a new stake in shares of Esperion Therapeutics in the fourth quarter worth approximately $82,000. ProShare Advisors LLC boosted its holdings in shares of Esperion Therapeutics by 75.2% during the fourth quarter. ProShare Advisors LLC now owns 62,549 shares of the biopharmaceutical company's stock worth $138,000 after purchasing an additional 26,843 shares during the period. Finally, Nuveen Asset Management LLC grew its position in Esperion Therapeutics by 48.6% during the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock valued at $6,862,000 after purchasing an additional 1,020,243 shares in the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.